Abstract: The present disclosure relates to compounds of formulae (I)-(VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.

Abstract: The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.

Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts and N-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by “a”, R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the eIF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts and N-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by “a”, R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the eIF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and/V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by “a”, R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the eIF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and/V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by “a”, R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

Abstract: A server hosting system provides managed servers for tenants of the server hosting system. Managed servers for different tenants can have the same IP addresses and fully-qualified domain names (FQDNs). Furthermore, the server hosting system provides routers for the tenants. The router for a tenant can receive a Domain Name System (DNS) update message. The DNS update message is a request for a DNS server to associate a tenant-side FQDN with a tenant-side IP address. This tenant-side IP address can concurrently be an IP address of a managed server of another tenant. In response to receiving the DNS update request, the router sends a DNS data message to a management system for the server hosting system. The DNS data message indicates the IP address, the tenant-side FQDN, and an IP address only associated with the given tenant.

Abstract: A server hosting system provides managed servers for tenants. Managed servers for different tenants can have the same IP addresses and fully-qualified domain names (FQDNs). A management system of the server hosting system receives a DNS data message from a tenant router in the server hosting system. The DNS data message specifies an IP address of one of the managed servers, a tenant-side FQDN for the managed server, and an IP address of the tenant router. The managed server and the tenant router are associated with a given tenant. The IP address is also an IP address of another one of the managed servers. In response, the management system obtains a management-side IP address and a management-side FQDN for the managed server. The management system then updates a Domain Name System (DNS) record to associate the management-side FQDN with the management-side IP address.

Abstract: A server hosting system provides managed servers for tenants of the server hosting system. Managed servers for different tenants can have the same IP addresses and fully-qualified domain names (FQDNs). Furthermore, the server hosting system provides routers for the tenants. The router for a tenant can receive a Domain Name System (DNS) update message. The DNS update message is a request for a DNS server to associate a tenant-side FQDN with a tenant-side IP address. This tenant-side IP address can concurrently be an IP address of a managed server of another tenant. In response to receiving the DNS update request, the router sends a DNS data message to a management system for the server hosting system. The DNS data message indicates the IP address, the tenant-side FQDN, and an IP address only associated with the given tenant.

Abstract: A server hosting system provides managed servers for tenants. Managed servers for different tenants can have the same IP addresses and fully-qualified domain names. A server manager for the server hosting system detects a deletion event for one of the managed servers. In response to detecting the deletion event, the server manager sends a web services request to a Domain Name Service (DNS) web service having a web API. The web services request requests invocation of a deregister method in the web API. The deregister method removes DNS records that associate a management-side fully qualified domain name (FQDN) for the managed server with a management-side IP address for the managed server. No other managed server in the server hosting system has the management-side IP address. No other managed server in the server hosting system has the management-side FQDN.